You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

~ Buy the GENOSYL (nitric oxide) Drug Profile, 2024 PDF Report in the Report Store ~

GENOSYL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Genosyl patents expire, and what generic alternatives are available?

Genosyl is a drug marketed by Vero Biotech Inc and is included in one NDA. There are twenty-four patents protecting this drug.

This drug has sixty patent family members in five countries.

The generic ingredient in GENOSYL is nitric oxide. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the nitric oxide profile page.

DrugPatentWatch® Generic Entry Outlook for Genosyl

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for GENOSYL?
  • What are the global sales for GENOSYL?
  • What is Average Wholesale Price for GENOSYL?
Summary for GENOSYL
International Patents:60
US Patents:24
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 17
Clinical Trials: 2
What excipients (inactive ingredients) are in GENOSYL?GENOSYL excipients list
DailyMed Link:GENOSYL at DailyMed
Drug patent expirations by year for GENOSYL
Recent Clinical Trials for GENOSYL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Geno LLCPhase 3
Geno LLCPhase 2

See all GENOSYL clinical trials

Pharmacology for GENOSYL
Drug ClassVasodilator
Physiological EffectVasodilation

US Patents and Regulatory Information for GENOSYL

GENOSYL is protected by twenty-four US patents.

Patents protecting GENOSYL

Conversion of nitrogen dioxide (NO.sub.2) to nitric oxide (NO)
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT

Nitrogen dioxide storage cassette
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nitrogen dioxide storage device
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Conversion of nitrogen dioxide (NO.sub.2) to nitric oxide (NO)
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT

Systems and devices for generating nitric oxide
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nitric oxide therapies
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Conversion of nitrogen dioxide (NO.sub.2) to nitric oxide (NO)
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Conversion of nitrogen dioxide (NO.sub.2) to nitric oxide (NO)
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT

Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT

Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Conversion of nitrogen dioxide (NO.sub.2) to nitric oxide (NO)
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Kit for the conversion of nitrogen dioxide (NO.sub.2) to nitric oxide (NO)
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT

Conversion of nitrogen dioxide (NO.sub.2) to nitric oxide (NO)
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT

Conversion of nitrogen dioxide (NO.sub.2) to nitric oxide (NO)
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT

Systems and devices for generating nitric oxide
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Conversion of nitrogen dioxide (NO.sub.2) to nitric oxide (NO)
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT

Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Systems and devices for generating nitric oxide
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Systems and devices for generating nitric oxide
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR DELIVERING NITRIC OXIDE TO A PATIENT WITH PULMONARY HYPERTENSION OR HYPOXIA

Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Conversion of nitrogen dioxide (NO.sub.2) to nitric oxide (NO)
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vero Biotech Inc GENOSYL nitric oxide GAS;INHALATION 202860-001 Dec 20, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Vero Biotech Inc GENOSYL nitric oxide GAS;INHALATION 202860-001 Dec 20, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Vero Biotech Inc GENOSYL nitric oxide GAS;INHALATION 202860-001 Dec 20, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for GENOSYL

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Linde Healthcare AB INOmax nitric oxide EMEA/H/C/000337
INOmax, in conjunction with ventilatory support and other appropriate active substances, is indicated:for the treatment of newborn infants ≥34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation;as part of the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function and oxygenation.
Authorised no no no 2001-08-01
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for GENOSYL

See the table below for patents covering GENOSYL around the world.

Country Patent Number Title Estimated Expiration
Canada 2713049 CONVERSION DE DIOXYDE D'AZOTE (NO2) EN MONOXYDE D'AZOTE (NO) (CONVERSION OF NITROGEN DIOXIDE (NO2) TO NITRIC OXIDE (NO)) ⤷  Sign Up
Canada 2763804 THERAPIES PAR OXYDE NITRIQUE (NITRIC OXIDE THERAPIES) ⤷  Sign Up
Japan 5950965 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for GENOSYL

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0560928 2002C/003 Belgium ⤷  Sign Up PRODUCT NAME: NITRIC OXIDE; REGISTRATION NO/DATE: EU/1/01/194/001 20010801
0786264 SPC/GB08/019 United Kingdom ⤷  Sign Up PRODUCT NAME: NITRIC OXIDE (NO); REGISTERED: UK EU/1/01/194/001 20010801
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.